genome editing, genetics & genomics

The International Commission on the Clinical Use of Human Germline Genome Editing claims the technology is still too risky for therapeutic use.

A new study in mice documents frequent undesirable repeats of DNA insertions that are not detected using standard PCR analysis.

Take a break from the bench to puzzle and peruse.

All six calves inherited the gene for preventing horn growth, but four also got a piece of the plasmid used to introduce the sequence to their dad—complicating regulatory approval.

Emails reveal that a facility in Dubai and others have asked geneticist He Jiankui for help in gene-editing embryos.

He Jiankui could face charges after an investigation finds he used techniques prohibited in China to edit the genes of twin girls.

Since He Jiankui presented his results at last week’s gene editing summit, researchers have raised concerns about his protocol, calling the procedure “amateurish” and “unconscionable.”

Despite a premature and ethically sketchy claim of genome editing in twin girls, an outright prohibition could blunt promising, responsible progress.

He Jiankui says he has successfully used CRISPR-Cas9 to tweak the genes of twins born earlier this month. Some independent experts are dubious.

Using bioinformatics, two teams of scientists identified inhibitory proteins for Cas9’s relative.

Two patients who received Sangamo’s zinc finger–based treatment for Hunter syndrome have lower biomarkers of the condition, but no signs of new enzyme production.

The Germany-based study will test an ex vivo genome-editing therapy for the inherited blood disorder β-thalassemia.

The results could lead to a treatment to lower cholesterol in patients with hypercholesterolemia.

Two studies find the genome-editing technique works best when cells have a faulty DNA-damage response that’s frequently present in cancers.  

Researchers have developed a variety of techniques to detect when CRISPR misses the mark.

Researchers identify antibodies for two commonly used Cas9 proteins in human blood. Investors take notice.

The 44-year-old patient has Hunter syndrome, which doctors hope to treat using zinc finger nucleases.

Scientists extend the capabilities of the CRISPR-Cas system to include precise manipulations of RNA sequences in human cells.

With the arrival of a new class of single-nucleotide editors, researchers can target the most common type of pathogenic SNP in humans.